Searched for: subject%3A%22drug%255C%2Beluting%255C%2Bstent%22
(1 - 7 of 7)
document
van der Hoeven, B.L. (author), Pires, N.M.M. (author), Warda, H.M. (author), Putter, H. (author), Quax, P.H.A. (author), Schalij, M.J. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
Diabetes mellitus (DM) is a strong predictor of in-stent restenosis. This may be due to a higher level of vascular inflammation. We hypothesized that diabetic patients will benefit from dexamethasone-eluting stents, since local inflammation and consequently neointimal growth are suppressed and no systemic side effects will occur. Methods: 21...
article 2008
document
Krom, Y.D. (author), Pires, N.M.M. (author), Jukema, J.W. (author), de Vries, M.R. (author), Frants, R.R. (author), Havekes, L.M. (author), van Dijk, K.W. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
Objective: Neointima formation is the underlying mechanism of (in-stent) restenosis. 17β-Estradiol (E2) is known to inhibit injury-induced neointima formation and post-angioplasty restenosis. Estrogen receptor alpha (ERα) has been demonstrated to mediate E2 anti-restenotic properties. However, the role of estrogen receptor beta (ERβ) is not...
article 2007
document
Monraats, P.S. (author), Kurreeman, F.A.S. (author), Pons, D. (author), Sewgobind, V.D.K.D. (author), de Vries, F.R. (author), Zwinderman, A.H. (author), de Maat, M.P.M. (author), Doevendans, P.A. (author), de Winter, R.J. (author), Tio, R.A. (author), Waltenberger, J. (author), Huizinga, T.W.J. (author), Eefting, D. (author), Quax, P.H.A. (author), Frants, R.R. (author), van der Laarse, A. (author), van der Wall, E.E. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
Genetic factors appear to be important in the process of restenosis after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. An important mediator in the inflammatory response is interleukin (IL)-10. Our aim was to study whether genetic variants in IL-10 predispose to the risk of restenosis. The...
article 2007
document
Pires, N.M.M. (author), Eefting, D. (author), de Vries, M.R. (author), Quax, P.H.A. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
Background: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prevent post angioplasty restenosis. Nevertheless, concerns about the safety of DES still exist. Objective: To investigate the vascular pathology and transcriptional responses to sirolimus and paclitaxel in a murine model for restenosis on underlying...
article 2007
document
Pires, N.M.M. (author), Jukema, J.W. (author), Daemen, M.J.A.P. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)
In 2001, the first human study with drug-eluting stents (DES) was published showing a nearly complete abolition of restenosis by using a sirolimus-eluting stent. This success was very encouraging to test new compounds in combination with the DES platform. Nevertheless, several other anti-restenotic compounds have been used in human clinical...
article 2006
document
Pires, N.M.M. (author), van der Hoeven, B.L. (author), de Vries, M.R. (author), Havekes, L.M. (author), van Vlijmen, B.J. (author), Hennink, W.E. (author), Quax, P.H.A. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
The introduction of drug-eluting stents (DES) to prevent in-stent restenosis is one of the major advances in interventional cardiology. Currently many types of DES are under evaluation for effectiveness and safety, a time-consuming and difficult procedure in humans. An animal model that allows rapid evaluation of the present and upcoming...
article 2005
document
Agema, W.R.P. (author), Monraats, P.S. (author), Zwinderman, A.H. (author), de Winter, R.J. (author), Tio, R.A. (author), Doevendans, P.A.F.M. (author), Waltenberger, J. (author), de Maat, M.P.M. (author), Frants, R.R. (author), Atsma, D.E. (author), van der Laarse, A. (author), van der Wall, E.E. (author), Jukema, J.W. (author), Gaubius Instituut TNO (author)
Aims To document the practice of interventional cardiology and the clinical restenosis rate, as well as the risk factors for clinical restenosis in an unselected population of patients in daily practice and to provide a perspective for the need of new devices such as drug-eluting stents. Methods and results A total of 3177 consecutive patients,...
article 2004
Searched for: subject%3A%22drug%255C%2Beluting%255C%2Bstent%22
(1 - 7 of 7)